Articles tagged with Cancer Patients
A recent study found pediatric cancer trial enrollment decreased from 40-70% in the 1990s to 19.9% in the current study. This decline is partly attributed to improved treatments for common childhood cancers, shifting focus to rarer and higher-risk cancers.
A new targeted drug, adavosertib, has demonstrated strong activity against uterine serous carcinoma (USC), a hard-to-treat form of the disease. In nearly one-third of patients, tumors shrank in response to the treatment.
A nationwide trial tests video counseling to help cancer patients quit smoking, addressing a significant public health concern. The study aims to provide evidence for tobacco treatment as standard care in community hospitals and clinics.
Researchers have discovered a gene signature, USC73, that can identify women with rare and aggressive uterine serous carcinoma who are unlikely to respond to standard chemotherapy. The high USC73 score is associated with poor patient survival, cancer cell proliferation, and low rates of complete response to treatment.
A study by King's College London found that cancer patients referred by GPs with suspected cancer had lower mortality rates and were more likely to be diagnosed at an earlier stage for breast, lung, and prostate cancer. Early GP referrals have made a significant impact in improving cancer outcomes in the NHS.
The NCCN Guidelines for Patients are among the most trustworthy resources for patients and caregivers seeking information on prostate cancer. The guidelines, written in an easy-to-learn format, provide essential information on diagnosis and treatment.
A study found that patients experienced higher rates of infections in the years leading up to a cancer diagnosis compared to those without cancer. The researchers discovered an association between specific infections and increased risk of certain types of cancer.
The seven European cancer centers of Cancer Core Europe have shared their experiences and measures taken to adapt to the COVID-19 pandemic. They emphasize the importance of adapting clinical activities, communication with patients, qualified personnel, and regional collaborations to ensure continuity in cancer care.
A new imaging technique combining high-resolution imaging with quantitative measurement of tissue elasticity can detect cancer within resected margins of breast-conserving surgery. The study found QME to have high sensitivity and specificity for detecting cancer, reducing the need for additional surgeries.
Researchers at Moffitt Cancer Center have identified the PERK protein as a critical molecular pathway controlling immunosuppression in tumor cells. By targeting PERK, cancer patients may experience reactivation of their immune system and enhanced effectiveness of immunotherapy treatments.
A recent study highlights the difficulties healthcare providers face when caring for cancer patients during a pandemic. The authors discuss strategies to mitigate these challenges and improve patient outcomes in Italy during the COVID-19 epidemic.
A clinical trial found that immunotherapy significantly slowed the worsening of urothelial cancer when given after platinum-based chemotherapy, with a 60% longer time to cancer progression compared to the control group. The switch maintenance immunotherapy approach is expected to become a standard of care for metastatic bladder cancer.
Patients with lung cancer in China who knew their diagnosis survived longer than those who did not, with a median survival time of 18.33 months versus 8.77 months. The study suggests that full disclosure of cancer diagnoses can benefit patients in the long term with proper communication and support.
A new study published in Cancer Research found that Indigenous American ancestry is associated with a greater incidence of HER2-positive breast cancer in Latinas. The study analyzed data from over 1,300 patients and found that women with higher proportions of IA ancestry were more likely to develop HER2-positive tumors.
A Phase II study found that 93% of patients with relapsed or refractory mantle cell lymphoma responded to CD19-targeting CAR T-cell therapy KTE-X19, with 67% achieving a complete response. The estimated progression-free survival and overall survival were 61% and 83%, respectively.
A genetic defect in 15% of children with medulloblastoma leads to disrupted protein production and metabolism, increasing the risk of cancer. The study identifies a new hereditary cause of medulloblastoma, which could lead to more effective treatment options for affected families.
During the COVID-19 outbreak in China, cancer patients underwent enhanced care measures to minimize SARS-CoV-2 transmission risk. These measures included strict infection control protocols and isolation procedures.
A Phase II trial found patients with metastatic castration-resistant prostate cancer who showed active T-cell responses in their tumors experienced prolonged survival after ipilimumab treatment. Researchers identified biomarkers associated with improved responses, including higher T-cell density and interferon-γ signaling.
A study found that physicians use varying strategies to address patients' worry about thyroid cancer, with some telling them it's a 'good cancer.' However, this approach may not be effective in alleviating worry. The research emphasizes the need for physician education and intervention to better support patients.
The study found that Medicaid expansions in states that adopted the Affordable Care Act were linked to a greater percentage of patients with localized head and neck cancer diagnosed at an early stage. Timely treatment led to improved survival rates for these patients. The researchers hope their findings will inform policy makers.
A new study found that cancer treatment with immune checkpoint inhibitors is associated with an increased risk of thyroid dysfunction, affecting up to 40% of patients. The type of cancer and specific combination of medications used can impact the likelihood of developing thyroid problems.
The Caravaggio study found that oral apixaban is at least as effective as dalteparin in preventing recurrent venous thromboembolism and major bleeding events in patients with cancer. The trial showed no significant difference in the risk of major bleeding, including gastrointestinal cancers, between the two treatments.
Researchers at the University of Virginia have identified inherited genetic variations that can predict patient outcomes and improve treatment success. By analyzing vast amounts of genetic data, doctors can now tailor treatments to individual patients' needs and genetic makeup.
A new blood test has been developed to detect a wide range of cancers, including breast, colorectal, and pancreatic cancer, with an accuracy rate of 99.3%. The test uses next-generation sequencing to analyze DNA methyl groups, which can indicate the presence of cancer.
A phase II clinical trial found that stereotactic ablative radiation (SABR) slowed disease progression in a subset of men with limited spread of prostate cancer. SABR treatment was associated with an expanded population of T cells, suggesting a full-body immune system response to their cancers.
Researchers at MD Anderson Cancer Center developed a combination therapy that reprograms effector T cells into persistent central memory T cells capable of self-renewal and effective cancer cell killing. This approach addresses the persistence challenge in cellular therapies, increasing their effectiveness.
Researchers estimated SARS-CoV-2 infection rate in cancer patients at a Wuhan hospital, revealing potential risks and health concerns. The study found that SARS-CoV-2 transmission occurred among cancer patients, emphasizing the need for enhanced precautions.
In a phase I study, fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated clinical activity in patients with non-breast/non-gastric cancer types with HER2 overexpression or mutation. The overall objective response rate was 28.3 percent, with greatest response rates for NSCLC and HER2-mutant NSCLC.
A new study found that taking higher daily step counts is associated with a lower risk of death from all causes. The study tracked over 4,800 U.S. adults and found that those who took 8,000 steps per day had a 51% lower risk compared to those who took 4,000 steps.
A study found that myelin, the protective coating of nerve cells, is dynamic and not inert as traditionally believed. This discovery has implications for treatment of multiple sclerosis and chemobrain, a type of myelin damage caused by chemotherapy drugs.
Researchers discovered that cancer cells induce lung tissue inflammation, releasing signals CXCL9 and CXCL10, which aid metastasis growth. The interaction between detached cancer cells and fibroblasts is crucial for metastatic colonization.
Researchers used AI to predict tumor sensitivity to three systemic cancer therapies in patients with advanced NSCLC. The models achieved an AUC of 0.77, 0.67, and 0.82 for nivolumab, docetaxel, and gefitinib, respectively.
A Phase II study found pembrolizumab to be effective in treating four rare cancer types with acceptable toxicity profiles. The treatment resulted in a median non-progression rate of 28% at 27 weeks, with complete response rates varying between 31-43% for each cancer type.
A phase 2 clinical trial conducted by the National Cancer Institute found that selumetinib improved outcomes for children with neurofibromatosis type 1 (NF1), shrinking inoperable tumors and reducing pain. The treatment also led to clinically meaningful improvements in quality of life, strength, and range of motion.
A study confirms racial disparities in treatment outcomes for pediatric brain cancer patients, with Black and Hispanic patients facing poorer prognoses after diagnosis and treatment, regardless of stage at diagnosis.
Researchers found that immunosuppressive therapy does not increase the occurrence or recurrence of vulvar or vaginal cancer in women with IBD, but an earlier onset was reported. Lymphomas were also found in some patients, which is rare in the genital tract.
A study published in Nature identified distinct microbial signatures associated with specific cancer types, including colon cancer and prostate cancer. Machine learning models trained on these signatures were able to distinguish between cancer patients and healthy individuals with high accuracy.
A University of Colorado Cancer Center study found that African American patients were half as likely as non-Hispanic whites to receive PET-CT imaging for non-small cell lung cancer, while Hispanics received it 70% as frequently. This disparity may be due to limited access to specialized imaging equipment and unconscious bias.
A collaborative research team from Dartmouth and Honduras found a high level of participation in rural cancer screening events, resulting in over 88% of identified individuals seeking follow-up care. The 'multiphasic' approach involved multiple cancer screenings in one event, which was well-received by local communities.
Researchers at UC have discovered a mechanism that could lead to new immunotherapies for patients with head and neck cancers. By understanding how calmodulin interacts with ion channels in immune cells, scientists may be able to develop new treatments to restore the ability of these cells to enter and kill tumors.
A new genetic test can identify patients with multiple myeloma who are at 'ultra high risk' of their cancer progressing aggressively early on. These patients have poorer survival rates and are unlikely to benefit from lenalidomide alone, highlighting the need for alternative treatment approaches.
The National Comprehensive Cancer Network (NCCN) has published a list of high-impact measures for assessing quality improvements in cancer care. The recommendations reflect a landscape analysis from leading oncology experts and include endorsement of 15 existing measures and seven new concepts proposed for development.
A self-paced online program guides adult cancer patients and older adults through advance care planning, improving their knowledge, decision-making skills, and readiness. Participants took modest action to begin planning, suggesting that such tools could support advance care planning initiatives in outpatient settings.
Research reveals bias and stereotyping among healthcare professionals when recruiting patients for cancer clinical trials. The study highlights language barriers, misconceptions, and negative perceptions of minority participants as challenges. Experts call for culturally tailored approaches to address biases in clinical trial recruitment.
Research by German Cancer Research Center and Hebrew University finds that intestinal bacteria reprogram DNA activity in gut mucosa cells, controlling healthy gut development and inflammation. Demethylating enzymes TET2 and TET3 play a key role in this process.
The Pancreatic Cancer Collective has awarded $16 million to four research teams pursuing preclinical work and clinical trials for new pancreatic cancer treatments. These breakthroughs aim to improve the five-year survival rate of 9%.
Researchers used AI to analyze digitized images of cancer tissues and found critical variations between black and white male patients, which could improve care for black patients with prostate cancer. The study suggests that there are biological differences in the disease that cannot be explained by other disparities.
A new testing method combining systematic biopsy with MRI-targeted biopsy leads to more accurate diagnoses and better treatment outcomes for prostate cancer patients. The study found that combined biopsy provided more accurate diagnoses than MRI-targeted biopsies alone, reducing the risk of overtreatment and undertreatment.
A new study found improvements in five-year survival rates for all cancers in young adults, with some cancer types showing little to no improvement since the 1970s. Treatment advances have led to steady improvements in estimated survival rates among adolescents and young adults.
A recent study has found that the five-year survival rate for adolescents and young adults with certain types of cancer has improved substantially over the past three decades. Leukemia and non-Hodgkin lymphoma have seen significant declines in mortality rates, with improvements ranging from 20-30 percentage points between 1975 and 2005.
A new clinical trial suggests that immunotherapy given before surgery for oral cavity cancers can elicit an immune response that shrinks tumors. Most patients (52%) experienced a clinical reduction of their primary tumor after immunotherapy, and four patients had more than 90% pathologic response.
A targeted therapy drug, everolimus, has been shown to extend progression-free survival for advanced head and neck cancer patients. Patients with TP53 mutations experienced a significant survival benefit, indicating potential as a treatment option for high-risk patients.
A study at MD Anderson Cancer Center found that using MLN4924 and dual treatment with anti-PD1 can induce durable, curative responses in patients with MMR-deficient and MSI cancers. The therapy approach shows promise as a novel therapeutic vulnerability for this type of cancer.
A novel blood test using gold nanoparticles detects cancer-derived extracellular vesicles, enabling earlier diagnosis and better treatment tracking. The technology has been successfully tested on melanoma patients and shows promise as a potential complement to existing cancer imaging technologies.
A new study finds that common malnutrition definitions do not apply equally to all cancers, highlighting the need for cancer-type specific definitions for preoperative risk assessment. The study's findings suggest that using one-size-fits-all definitions could result in overestimating or underestimating a patient's risk of complication...
A clinical trial led by Queen Mary University of London found that immune therapy drug pembrolizumab significantly reduced the risk of cancer recurrence in patients with early triple negative breast cancer. Nearly 65% of women showed no sign of cancer after treatment, compared to 51% on chemotherapy alone.
Researchers from CNIO and Cabimer reveal DNA topological problems cause endogenous DNA breaks leading to lymphoma development. The study highlights a strong causal relationship between topological problems and cancer development in ATM-deficient lymphoid malignancies.
A clinical trial has found that a combination of ipilimumab and nivolumab immunotherapies can shrink tumors in 44% of patients with high-grade neuroendocrine cancer. The trial, DART, offers new hope for rare cancer treatment, which accounts for almost a quarter of all cancers diagnosed worldwide.
Dr. John E. Dick has been honored with the 2020 Pezcoller-AACR Award for his discovery of leukemic stem cells and development of a hematopoietic xenograft assay. This work has provided crucial insights into leukemia progression and potential therapeutic targets.
Researchers at Yale Cancer Center discovered that a small amount of the PD-L1 biomarker can predict long-term survival benefits from using pembrolizumab in patients with advanced lung cancer. The study found that overall survival was about 99% one year after discontinuing treatment, and ranged from 23% to 35% three years after treatment.